ArticleFrontiers in oncology2026
Resection margins in transoral oropharyngeal surgery: comparative analysis of robotic and VITOM Eagle-assisted exoscopic approaches.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transoral robotic surgery (TORS) is widely regarded as the current benchmark minimally invasive approach for early-stage oropharyngeal squamous cell carcinoma (OPSCC), although access remains limited by cost and infrastructure. Three-dimensional exoscopic surgery (3Des) has recently emerged as a lower-cost, team-shared alternative, but clinical evidence in OPSCC is still limited. This study compared the pathological radicality and surgical margin adequacy of transoral resections performed using a robotic platform versus a 3D exoscope. Methods: This retrospective cohort study included 94 consecutive patients with OPSCC treated between 2016 and 2026 by transoral surgery using either the da Vinci Xi system (robotic group, R; n = 75) or the VITOM Eagle 3D exoscope (exoscopic group, E; n = 19). Margins were classified as positive (tumor at inked margin), close (<1 mm), or negative (≥1 mm). Superficial and deep margin distributions, perioperative outcomes, and early oncologic events were compared between platforms. Results: Positive margins occurred in 14.7% of R patients and 5.3% of E patients. Close margins (<1 mm) were observed in 12.0% and 26.3%, respectively, while margins ≥1 mm were achieved in 73.3% and 68.4%. Platform-specific analysis demonstrated comparable superficial and deep margin control (superficial ≥1 mm: 85.3% R vs. 73.7% E, Conclusions: Three-dimensional exoscopic transoral surgery achieved pathological margin status and perioperative safety comparable to those obtained with the robotic platform. By combining stereoscopic visualization, shared operative field view, and compatibility with CO
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.